Hereditary Cancer Panel denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why This Denial Happens

BCBS coverage policies for hereditary cancer panel testing sometimes limit how many times such testing may be performed — for example, allowing a single hereditary panel per lifetime or per diagnosis. A quantity-limits denial arises when a patient has had prior genetic testing and now requires an updated or expanded panel, or when a second test is ordered because the first yielded a variant of uncertain significance that warrants re-evaluation as new evidence becomes available. Because genetic knowledge evolves rapidly, a panel performed several years ago may no longer capture what is clinically necessary today.

## Why This Is Appealable

A quantity-limits denial is appealable when the clinical circumstances for the new test are materially different from those that justified the prior test. The appeal must show either that the prior test was a different service (fewer genes, different indication), that new clinical information has emerged since the prior test, or that re-testing is specifically indicated by the applicable guideline organization's current recommendations. Quantity limits that do not accommodate clinically indicated re-testing raise questions about whether the plan is applying a blanket administrative rule rather than individualized medical necessity criteria.

## Federal Appeal Framework

• Internal appeal: File within the deadline on the denial notice. BCBS must render a decision within 30 days (pre-service standard) or 60 days (post-service).
• External review (ACA §2719): After final internal denial, independent external review is available — generally within four months. The external reviewer applies objective clinical standards and is not bound by BCBS's quantity-limit rule alone.
• Expedited review: Available when urgent treatment decisions depend on test results.
• ERISA §503: Self-funded plan members retain full-and-fair review and federal court rights after exhaustion.

## Documentation to Gather

1. Prior test records — the name, date, performing lab, and gene list of all prior genetic tests, demonstrating how they differ from the panel now requested. 2. Ordering clinician's letter — explaining the specific clinical reason a new or expanded panel is necessary, including any new diagnoses, new family history, or updated guideline recommendations that have emerged since the prior test. 3. Documentation of variant of uncertain significance (VUS) — if the prior test returned a VUS that has since been reclassified or that warrants confirmatory testing, include the lab's updated interpretation or reclassification letter. 4. Applicable guideline organization's current recommendation — reference the organization (e.g., NCCN) and submit the current guideline document as a labeled exhibit showing re-testing or expanded testing is appropriate in these clinical circumstances. 5. BCBS published coverage policy — identify the exact quantity-limit language and any exceptions it provides.

## Criteria-Mapping Structure

List each element of BCBS's quantity-limit exception criteria in a two-column table. On the right, provide the specific clinical fact — from the chart, prior test records, and the clinician's letter — that satisfies each element. If no formal exception pathway exists in the policy, the appeal should argue that applying the quantity limit to these circumstances constitutes a denial of coverage for a medically necessary service, and request that BCBS apply individualized medical necessity review rather than the blanket limit.